Morpholinos, morpholino upregulating, and associated methods
Various methods and compositions relating to vascular endothelial growth factor receptor 2 (VEGFR2) are provided. In one aspect, a method of increasing expression of the soluble form of VEGFR2 (sVEGFR2) in a subject can include binding an antisense morphoiino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 niRNA is spliced into a sVEGFR2 isoform.
1. A pharmaceutical composition for increasing expression of sVEGFR2 in a subject comprising a pharmaceutically effective carrier including a morpholino capable of binding to an exon13-intron13 splicing site of VEGFR2 mRNA to facilitate increased expression of sVEGFR2, wherein the morpholino is selected from SEQ ID NOs: 1, 2, 3, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43.
2. The composition of claim 1 , wherein the morpholino has a sequence of SEQ ID NO: 001.
3. A method of increasing expression of sVEGFR2 in a subject, comprising administering to the subject an antisense morpholino capable of binding to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into a sVEGFR2 isoform, wherein the morpholino is selected from SEQ ID NOs: 1, 2, 3, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43.
4. The method of claim 3 , wherein the morpholino has a sequence of SEQ ID NO: 001.
5. A method of inhibiting neovascularization in a subject, comprising administering to the subject an antisense morpholino capable of binding to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into a sVEGFR2 isoform, wherein the morpholino is selected from SEQ ID NOs: 1, 2, 3, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43.
6. The method of claim 5 , wherein the morpholino has a sequence of SEQ ID NO: 001.